

17–19 September 1998

The British Prostate Group 3rd International Symposium on Prostate Disease in conjunction with the British Institute of Radiologists
Oxford, UK

Further information from:

BPG Secretariat, c/o British Association of Urological Surgeons, 35/43 Lincoln's Inn Fields, London WC2A 3PN, UK.
Tel: + 44(0) 171 405 1390; Fax: + 44 (0) 171 404 5048.

25–28 September 1998

22nd Congress of the International Association for Breast Cancer Research
Athens, Greece

Further information from:

Congress Secretariat, Erasmus Conference Centre, 227, Kifissias Ave., 145 61 Kifissia-Athens, Greece. Tel: + (301) 6125022/3; Fax: + (301) 6125021.

1–3 October 1998

13th Congress of the European Society for Urological Oncology and Endocrinology
Innsbruck, Austria

Further information from:

Ms Martina Neuhauser, Department of Urology, University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.
Tel: + 43 512 504 4874; Fax: + 43 512 504 4873;
Email: ESUOE-Innsbruck@uibk.ac.at

24–27 October 1998

Symposium on predictive Oncology and Therapy
Nice, France

Further information from:

Professor H E Nieburgs MD. Tel: 212 534 4991; Fax: 508 856 1567; Email: canprev@cancerprev.org;
<http://www.cancerprev.org>

Errata

Emergency admission for cancer – a matter of survival?

In the article entitled 'Emergency admission for cancer – a matter of survival?', which appeared in *Br J Cancer* 77: 353–358, the ratios of the number of patients who died/number of patients at risk in the emergency admission group in Figure 1 are inverted. This should be corrected as follows:

'T = 10 months: 86/72, T = 30 months: 114/36, T = 50 months, 121/22.'

We apologize for the typographical error that occurred in the original publication.

M Porta, E Fernandez, J Belloc, N Malats, M Gallén and J Alonso

Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours

In the article entitled 'Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours, which appeared in *Br J Cancer* 77: 153–158, the discussion section on page 157 regarding administration of ifosfamide should be corrected as follows:

'...active when administered intravenously...'

We apologise for the error that occurred in the original publication.

LC Pronk, D Schrijvers, JHM Schellens, EA de Bruijn, ASTh Planting, D Locci-Tonelli, V Groult, J Verweij and AT van Oosterom